美股新聞 標題聯播 · 近 24 小時 336 則 · 29 個來源 · 最新 9/20 04:53
本站只列標題、來源、時間與原文連結,不重製內文;著作權屬原媒體與原作者。新聞稿通路(PR Newswire、Business Wire、GlobeNewswire)是公司自己發的,屬第一手;媒體是轉述。
全部 · DFTX近 30 天 11 則 · 第 1 / 1 頁
- Definium Reports Second Phase III Success in Anxiety Disorder Program
- Definium Therapeutics (DFTX) Stock May Trade At A Premium Despite Phase 3 DT120 Results
- Definium tees up regulatory submission for psychedelic on Phase III hat trick
- Why Definium Therapeutics (DFTX) Is Up 5.7% After Second Positive Phase 3 DT120 Anxiety Trial Result
- The Psychedelics News That Sent Definium, Already Up 190% This Year, Soaring
- Psychedelics Are Wall Street’s Next Trip. Why This Biotech Stock Is Already Up 200%.
- Sector Update: Healthcare Stocks Rise in Afternoon Trading
- Definium Therapeutics Announces Positive Topline Results from Phase 3 Panorama Study of DT120 ODT in Generalized Anxiety Disorder
- Definium Therapeutics to Discuss Topline Results from Phase 3 Panorama Study in Generalized Anxiety Disorder on September 14, 2026
- Definium Therapeutics to Present Topline Data from Phase 3 Emerge and Voyage Trials Across Major Depressive Disorder and Generalized Anxiety Disorder at Psych Congress 2026
- Definium Therapeutics Receives Breakthrough Therapy Designation for DT120 (lysergide) Orally Disintegrating Tablet (ODT) in Major Depressive Disorder (MDD) Following Positive Phase 3 Results
- Weekly Roundup on the Cannabis Sector & Psychedelic Sector
中文標題是機器翻譯(NLLB 模型,不外送資料),專有名詞靠對照表,語意以英文原題為準。預設藏掉:選股文與自動生成站(Motley Fool、24/7 Wall St、Trefis、MarketBeat…)、加密幣、律師事務所的股東訴訟廣告、非英文、新聞稿裡的人事任命 / 出席活動 / 得獎、個人理財專欄,以及通路稿標題對不到上市公司的。個股標籤是從標題辨識的(通路標準寫法 (NASDAQ: NVDA)、公司名對照);帶「?」的是從摘要辨識、信心較低。來源等級 A / B / C 只影響精選排序,不是對媒體的評價。